How we treat Richter Syndrome... from CLL experts at the Mayo Clinic
Richter syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). RS occurs in approximately 2% to 10% of CLL patients during the course of their disease, with a transformation rate of 0.5% to 1% per year.
Richter's can occur at any time, but the length of time to first treatment and chemoimmunotherapy are factors.
On March 10, 2014, an unprecedented unification of more than 30 Canadian patient groups, physicians and health care charities and led by Kidney Cancer Canada, launched CanCertainty, a campaign calling for equal and fair treatment for all Canadians.
CanCertainty represents a growing coalition of organizations working together to ensure all Canadian cancer patients will have fair and equal access to the treatment they need, whether intravenous (IV) or oral. As an umbrella organization focused on advancing patient and caregiver interests, the Canadian Cancer Action Network (CCAN) is proud to support this effort financially as we lend our voice to the following call for action to the governments of Ontario,Nova Scotia, Prince Edward Island, New Brunswick, and Newfoundland and Labrador to join the rest of the country in providing fair and equivalent access to oral and IV anti-cancer treatments.
According to the attached white paper developed by the Cameron Institute, a not-for-profit, public policy think tank, “it is estimated an investment of $28 - $93 million will ensure all patients in Ontario have access to oral medications. The investment is also estimated to lead to at least a 17 per cent reduction in overall chemotherapy unit costs. The same holds true, proportionally, for Nova Scotia and Newfoundland and Labrador as well.” For more information, including the CNW press release, relevant background information, please visit the link below.
Imbruvica (Ibrutinib) FDA approved in previously treated CLL
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy.
This applies to use in the U.S. only. Hopefully the Health Canada approval will follow and then
the pCODR funding studies and recommendations to the provinces can begin. This can be a lengthy
process. For more information on Cancer Drug Approvals in Canada here is a good overview...
A Canadian Perspective on the Treatment of Unfit Patients with Chronic Lymphocytic Leukemia
This paper discusses two major issues physicians encounter when treating unfit patients with CLL: (i) What factors enter into the decision that a patient is unfit for FCR therapy? (ii) What are the best treatment options for those patients who are deemed unfit? In addition to reviewing the current evidence, the regional practices of three Canadian experts from Nova Scotia, Quebec, and Alberta will be explored.
PDF LINK HERE
Feb 3 , 2014
Health Canada/GSK on Arzerra (ofatumumab) and HepB
GSK, in consultation with Health Canada, would like to inform you of important new updates to the recommendations for screening, monitoring and management of Hepatitis B reactivation in patients treated with ARZERRA™ (ofatumumab).
ARZERRA™ is an anti-CD20 antibody that is authorized in Canada under a Notice of Compliance with conditions, for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
SEE DETAILS... LINK HERE
January 27, 2014
New CLL trial in Toronto
New Phase 1/2 clinical trial for Ruxolitinibn by Dr. Spaner at Sunnybrook in Toronto for 65 and over who are unfit for FCR... also 17p deleted of any age.
Details LINK HERE
January 10, 2014
LLC en français?
This is a link to a French CLL/SLL website...
might give it a try.
Dec 10 , 2013
How Cancer Drugs are Approved and Funded in Canada
This tutorial explains the process that decision makers in Canada follow to decide whether to publicly fund new cancer drugs. You’ll learn who is involved in this process, and how health benefits, costs and values play into the decision. At the end of the tutorial, you should be able to answer the following questions:
Which groups make decisions in Canada about publicly funded cancer drugs and how are those decisions made?
◊ How do we know if drugs work and are better than current treatment?
◊ How do costs and benefits fit into the decision making process?
◊ What is a fair decision?
◊ How are decision makers held accountable to the public?
◊ How can you get involved in cancer drug funding decision making panels?
The principles described in this tutorial also apply to decisions about other non-
cancer drugs and new health care technologies.
LINK HERE PDF TUTORIAL
Nov 2, 2013
Gazyva, obinutuzumab...FDA APPROVED
The U.S. Food and Drug Administration today approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).
FDA LINK HERE
Nov 1 , 2013
Canadian CLL Study
Fludarabine-containing regimens are typically used in the frontline treatment of chronic lymphocytic leukaemia (CLL), but relapse is common and response rate with re-treatment is generally inferior to response as first-line treatment.There is thus a need to develop new and non-cross-resistant drug combinations for relapsing patients.
Inhibition of histone deacetylases (HDACs) using pharmacological agents, such as depsipeptide, suberoylanilide hydroxamic acid and valproic acid (VPA) is a novel strategy to treat such patients.
LINK HERE TO PDF
Oct 30, 2013
9th Canadian CLL Meeting Report - Winnipeg, MB, October 3-4, 2013
The annual high-level science meeting brings together oncologists, hematologists, researchers and trainees across Canada to hear about CLL clinical trials in Canada, and basic research on CLL. The poster session, initiated last year, gave trainees and researchers an opportunity to present their findings and selected posters were presented orally.
New FDA warning for Rituxan (MabThera) and Arzerra (ofatumumab) with regards to reactivation of hepatitis B virus (HBV) infection
The U.S. Food and Drug Administration (FDA) has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection.
The revised labels also will include additional recommendations for screening, monitoring, and managing patients on these drugs to decrease this risk.
PLEASE CONSULT YOUR DOCTOR.
See full information here
Sept 25, 2013
Increased risk of second malignancies in CLL as compared with follicular lymphoma patients: a Canadian population-based study
Treated CLL patients had a 1.7-fold increased risk of second cancers compared with untreated CLL patients. As compared with untreated FL patients, untreated CLL patients had a two-fold increased incidence of second malignancies.
Chronic lymphocytic leukaemia patients have an inherent predisposition to second cancers and the incidence is further increased by treatment.
Infinity Pharmaceuticals, Inc. today announced that, in the fourth quarter of 2013, it expects to initiate a Phase 3 trial of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
This randomized study is designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg twice daily compared to ofatumumab in approximately 300 relapsed or refractory patients.
Aug10 , 2013
Revlimid (lenalidomide) CLL Trial Discontinued
Celgene Will Discontinue Phase III ORIGIN® Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Based on an imbalance in deaths, specifically 34 deaths out of 210 patients in the lenalidomide arm compared to 18 deaths out of 211 patients in the chlorambucil arm, FDA placed the study on clinical hold. No specific causality for this imbalance has been identified to date.
Results from the CLL-008 study will be presented at an upcoming medical conference.
July 20, 2013
Flow Cytometry ~ Everything you need to know and more...
Flow Cytometry is a blood test used to diagnose CLL. This video tutorial education program explains how flow cytometry actually works.
This takes about 12 minutes to view... Will NOT work on iPad etc. Needs Flash Player 8
Information on the CLL CANADA website (www.cllcanada.ca) is intended to be used for general information and educational purposes
and should not replace consultation with healthcare professionals. The information on this site is provided by CLL patients and caregivers.
Consult a qualified healthcare professional before making any medical decisions or if you have questions about your individual medical situation. Please, do not self medicate.